 |
free hosting image hosting hosting reseller online album e-shop famous people |  |
  |
||
|
free hosting image hosting hosting reseller online album e-shop famous people | |
|
||
Mesothelioma Cancer Online
|
|
There are generally three phases involved in mesothelioma cancer clinical trials, and all three phases must be successful before the FDA (Food & Drug Administration) can consider approving the cancer drug or treatment.
Phase I: This takes place after lab and animal testing has been successfully performed. However, during this stage the effects on human patients of the drug or treatment being tested needs to be closely monitored. Phase II: Following the evaluation of the safety of the cancer treatment (during phase I) this phase assesses how effective the cancer drug or treatment is. The patients' affected areas are carefully monitored to see what effects the cancer treatment has had on the cancer. Side effects as well as positive and negative effects are recorded and carefully assessed during this phase. Phase III: This is where large numbers of patients are enrolled for testing of the cancer treatment or drug. There is generally a 'control group' who are given a standard cancer treatment, whereas the test group are given the new treatment. This enables researchers to compare the effects of the new cancer treatment against the standard one. Patients are very closely monitored during this phase, and cancer treatment is stopped upon the onset of any severe side effects. There are a number of standard questions that a cancer researcher needs to be able to answer from the results of mesothelioma cancer clinical trials, such as: Whether the treatment is likely to help patients? Whether the treatment works? Whether the treatment is more effective than other standard treatments available? What sort of side effects the treatment has? Whether the benefits outweigh the risks and side effects? Whether the treatment is likely to help a particular group of patients, and if so which group? Although doctors often recommend joining mesothelioma cancer clinical trials to their patients (subject to eligibility) it is the patient's decision as to whether or not he or she wishes to be part of a test group. Patients often agree to mesothelioma cancer clinical trials in the hope that they can benefit from a new cancer treatment as well as help the medical profession to find a drug that can help others in the same situation. However, refusing to be part of a mesotheliom cancer clinical trial does not in any way affect the patient's right to standard cancer treatment or medication. |